MedTrace Logo

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

NCT04470804 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-02-28

No results posted yet for this study

Summary

Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine A and /or steroids are the first line therapy but some patients were refractory or intolerance to the treatment. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of sirolimus for newly diagnosed primary acquired PRCA.

Conditions

  • Pure Red Cell Aplasia, Acquired

Interventions

DRUG

Sirolimus

Sirolimus treats in experimental group

DRUG

Cyclosporine A

Cyclosporine A uses for active comparator group.

Sponsors & Collaborators

  • Bing Han

    lead OTHER

Principal Investigators

  • Bing Han, PhD · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-07-30
Completion
2022-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470804 on ClinicalTrials.gov